ACPH Acacia Pharma Group PLC

TR-1: Standard form for notification of major holdings

TR-1: Standard form for notification of major holdings

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i
 
1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:ACACIA PHARMA GROUP PLC
1b. Please indicate if the issuer is a non-UK issuer  (please mark with an “X” if appropriate)
Non-UK issuer 
2. Reason for the notification (please mark the appropriate box or boxes with an “X”)
An acquisition or disposal of voting rightsX
An acquisition or disposal of financial instruments 
An event changing the breakdown of voting rights 
Other (please specify)iii: 
3. Details of person subject to the notification obligationiv
NameJULIAN CLIVE GILBERT
City and country of registered office (if applicable)Royston, UK
4. Full name of shareholder(s) (if different from 3.)v
Name 
City and country of registered office (if applicable) 
5. Date on which the threshold was crossed or reachedvi:14 January 2020
6. Date on which issuer notified (DD/MM/YYYY):15/10/20
7. Total positions of person(s) subject to the notification obligation
 % of voting rights attached to shares (total of 8. A)% of voting rights through financial instruments

(total of 8.B 1 + 8.B 2)
Total of both in % (8.A + 8.B)Total number of voting rights of issuervii
Resulting situation on the date on which threshold was crossed or reached2.98% 2.98%63,588,865
Position of previous notification (if

applicable)
N/A N/A 
       





8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii
A: Voting rights attached to shares
Class/type of

shares


ISIN code (if possible)
Number of voting rightsix% of voting rights
Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)
Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)
Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)
Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)
Ordinary shares of 2p ISIN GB00BYWF9Y761,907,670 2.98% 
     
     
SUBTOTAL 8. A1,907,6702.98%
 



 
B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))
Type of financial instrumentExpiration

date
x
Exercise/

Conversion Period
xi
Number of voting rights that may be acquired if the instrument is

exercised/converted.
% of voting rights
     
     
     
  SUBTOTAL 8. B 1  
 



 
B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))
Type of financial instrumentExpiration

date
x
Exercise/

Conversion Period
xi
Physical or cash

settlementxii
Number of voting rights % of voting rights
      
      
      
   SUBTOTAL 8.B.2  
 



 



 
          



9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an “X”)
Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiiiX
Full chain of controlled undertakings through which the voting rights and/or the

financial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary)
 
Namexv% of voting rights if it equals or is higher than the notifiable threshold% of voting rights through financial instruments if it equals or is higher than the notifiable thresholdTotal of both if it equals or is higher than the notifiable threshold
Julian Clive Gilbert2.98% 2.98%
    
    
    
    
 
10. In case of proxy voting, please identify:
Name of the proxy holder 
The number and % of voting rights held 
The date until which the voting rights will be held 
 
11. Additional informationxvi
 
     



Place of completion 
Date of completion15 January 2020



Annex: Notification of major holdings (to be filed with the FCA only)
 
A: Identity of the person subject to the notification obligation
Full name (including legal form for legal entities)Julian Clive Gilbert
Contact address (registered office for legal entities)47 Hay Street, Steeple Morden, Royston, Herts SG8 0PD
E-Mail
Phone number / Fax number 07946 494981
Other useful information

(at least legal representative for legal persons)
 
  
B: Identity of the notifier, if applicable
Full nameJulian Clive Gilbert
Contact address47 Hay Street, Steeple Morden, Royston, Herts SG8 0PD
E-Mail
Phone number / Fax number 07946 494981
Other useful information (e.g. functional relationship with the person or legal entity subject to the notification obligation) 
 
C: Additional information
 
   
EN
15/01/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Acacia Pharma Group PLC

 PRESS RELEASE

Scheme of arrangement becoming effective

Scheme of arrangement becoming effective Acacia Pharma Group PLC THIS ANNOUNCEMENT CONTAINS REGULATED INFORMATION NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION FOR IMMEDIATE RELEASE 9 June 2022, 1.00 p.m. (Brussels time) RECOMMENDED ACQUISITION of ACACIA PHARMA GROUP PLC by EAGLE PHARMACEUTICALS, INC. to be effected by means of a scheme of arrangement under Part 26 of the Companies Act 2006 Scheme becomi...

 PRESS RELEASE

Court Sanction of the Scheme of Arrangement

Court Sanction of the Scheme of Arrangement Acacia Pharma Group PLC THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AND REGULATED INFORMATION NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION FOR IMMEDIATE RELEASE 7 June 2022, [1.00] p.m. (Brussels time) RECOMMENDED ACQUISITION of ACACIA PHARMA GROUP PLC by EAGLE PHARMACEUTICALS, INC. to be effected by means of a scheme of arrangement under ...

 PRESS RELEASE

Acacia Pharma Results of the Court Meeting and the General Meeting hel...

Acacia Pharma Results of the Court Meeting and the General Meeting held on 19 May 2022 Acacia Pharma Group PLC THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AND REGULATED INFORMATION NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION FOR IMMEDIATE RELEASE 20 May 2022, 8:00 a.m. (Brussels time) RECOMMENDED ACQUISITION of ACACIA PHARMA GROUP PLC by EAGLE PHARMACEUTICALS, INC. to be effected b...

 PRESS RELEASE

Publication of Annual Report and Financial Statements for the Year end...

Publication of Annual Report and Financial Statements for the Year ended 31 December 2021 This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No 596/2014. Cambridge, UK and Indianapolis, US – 29 April 2022, 23:00 CEST: Acacia Pharma Group plc (“Acacia Pharma”, the “Group” or the “Company”) (EURONEXT: ACPH), a hospital pharmaceutical company focused on the development and commercialization of new products aimed at improving the care of patients undergoing significant treatments such as surgery, other invasive procedures or cancer ...

 PRESS RELEASE

Publication of Scheme Document

Publication of Scheme Document Acacia Pharma Group PLC THIS ANNOUNCEMENT CONTAINS REGULATED INFORMATION NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION FOR IMMEDIATE RELEASE 27 April 2022, 12:00 p.m. (Brussels time) RECOMMENDED ACQUISITION of ACACIA PHARMA GROUP PLC by EAGLE PHARMACEUTICALS, INC. to be effected by means of a scheme of arrangement under Part 26 of the Companies Act 2006 Publication of Schem...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch